{"id":"W4399480368","doi":"10.1200/jco.24.01001","title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Ono Pharmaceutical; Chugai Pharmaceutical; Seagen; MacroGenics; Astex Pharmaceuticals; Novocure; Regeneron Pharmaceuticals; Yuhan; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Internal medicine; Oncology; Phases of clinical research; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001929646,0.001215053,0.002530653,0.0004113333,0.0002435088,0.0008365449,0.0006960632,0.001002776,0.003110719],"category_scores_gemma":[0.00158731,0.0005061643,0.001726097,0.0003384721,0.0009142124,0.0009860384,0.0003819819,0.002595555,0.0006294445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006258115,"about_ca_system_score_gemma":0.0008814223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003343248,"about_ca_topic_score_gemma":0.001123401,"domain_scores_codex":[0.9991609,0.0004962545,0.00005898856,0.0001109776,0.00006573059,0.0001072104],"domain_scores_gemma":[0.998831,0.0003421875,0.0002633673,0.00009423681,0.00004625549,0.0004230056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9290527,0.01557159,0.00136698,0.0003348296,0.0008757121,0.00003922822,0.00005539082,0.000846369,0.008120527,0.00009993434,0.0007425215,0.04289427],"study_design_scores_gemma":[0.558151,0.4302995,0.005743857,0.00003274085,0.000796444,0.00009215323,0.00003714408,0.001469466,0.002325229,0.0002192722,0.0008128637,0.00002031612],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942297,0.002097167,0.0005920589,0.0003269596,0.0002274148,0.0009491144,0.0004183378,0.00007939019,0.001079844],"genre_scores_gemma":[0.9946989,0.001156146,0.0007605654,0.0003036898,0.0002774737,0.001047925,0.0005054952,0.00001832013,0.001231519],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003110719,"threshold_uncertainty_score":0.01040637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04980772707266565,"score_gpt":0.4339217826342359,"score_spread":0.3841140555615702,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}